wrong

corrected

A new therapeutic strategy in cancer

Several years ago, I was asked to explain the difference between malignant and normal cells in a friend --> at a friend's party. Of course it is not wise to tell them  honestly <that> I am only interested in <the> non-professional field_(or more frankly, just too lazy to remerber any medical knowledge). 

At that time I pretended to be professional and only replied them <in> one sentence, “Cancer cells share morphology --> morphological abnormalities in the nucleous/ nucleolus with normal ones'. I feel that this maybe the most basic knowledge in <the> cancer field. 

However, any talented researches were --> research was derived from basic knowledge. This principle impressed me more when I happened to read a creative literature in Cancel --> Cancer (?!) Cell today.

The author just asked a question with simple logic:

If morphologic abnormalities of the nucleolus has been recognized as diagnostic --> a diagnosis for cancer for even one century, is it possible that some special actions in nucleolus_(...transcription.etc.) is in major --> are predominantly responsible for keeping malignancy?

Therefore, Pol-1, a very important enzyme in rRNA transctiption --> transcription, attracts their attentions.

Strikingly, they found <that> elevated rRNA transcription by Pol-1 is a stalwart feature of cancer. Then an agent was chosed to inhibit the expression of <the> Pol-1 enzyme. This step really means a lot in --> of improvements of --> in cancer therapies because the inhibition of Pol-1 and the following rDNA transcription unexpectly show a selective feature.

It could kill malignant cells but keep <the> normal cell population viable. Because of this high selectivity, Pol-1 inhibitor_(..CX-5441..) shows a promising role in the therapy of cancer.

Creative discoveries stem from previous knowledge. :)))

Reference: Cancer Cell 22, 51-65, July 10, 2012 Megan J.Bywater etc.